Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Chief Commercial Officer | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,719 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 3,288 · Balance 48,719 F1: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F2: This transaction was executed in multiple trades at prices ranging from $33.52 to $34.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $33.52 to $34.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2021 Filed Dec 15, 2021 00:54 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-21-000264 · wf-form4_163952966749548.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 705 shares acquired on August 31, 2021, under the Issuer's employee stock purchase plan. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 4,737 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · derivative · entry 5 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,695 Underlying: Common Stock · 4,737 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. F4 · derivative.exercise_date: 25% of the 24,610 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 5,263 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · derivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479 Underlying: Common Stock · 5,263 shares Expires 2027-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. F3 · derivative.exercise_date: 25% of the 11,484 shares originally subject to the option vested on July 21, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 10,000 | $75.40 | $754,000.00 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · nonDerivative · entry 3 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,827 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.00 to $75.90, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 4,737 | $2.39 | $11,321.43 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 5,263 | $2.36 | $12,420.68 |
DisclosureSEC source: 0001447362-21-000150 · wf-form4_162430627131283.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.